表紙:生物製剤受託開発の世界市場 (2020-2027年):微生物・哺乳類・その他
市場調査レポート
商品コード
959610

生物製剤受託開発の世界市場 (2020-2027年):微生物・哺乳類・その他

Biologics Contract Development Market Size, Share & Trends Analysis Report By Source (Mammalian, Microbial), By Product Service Type, By Disease Indication (Oncology, Immunological Disorders), By Region, And Segment Forecasts, 2020 - 2027

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 144 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
生物製剤受託開発の世界市場 (2020-2027年):微生物・哺乳類・その他
出版日: 2020年08月18日
発行: Grand View Research, Inc.
ページ情報: 英文 144 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の生物製剤受託開発の市場規模は予測期間中8.8%のCAGRで推移し、2027年には112億米ドルの規模に成長すると予測されています。生物製剤開発における先端技術の利用の拡大、新興諸国における臨床試験環境、R&Dのアウトソーシングの増加、バイオ製薬企業とCDO間のM&Aや提携などの増加などの要因が同市場の成長を推進する見通しです。

当レポートでは、世界の生物製剤受託開発の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、原料・製品&サービス区分・適応症・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

  • 市場区分・市場範囲
  • 市場力学
  • 普及・成長見通しマッピング
  • 市場分析ツール

第4章 市場分析・予測:原料別

  • 微生物
  • 哺乳類
  • その他

第5章 市場分析・予測:製品・サービス別

  • 細胞株開発
  • プロセス開発
  • 下流プロセス:製品別
  • その他

第6章 市場分析・予測:適応症別

  • 腫瘍
  • 免疫疾患
  • 心血管疾患
  • 血液疾患

第7章 市場予測・動向分析:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 企業プロファイル

  • Wuxi Biologics
  • Abzena Ltd.
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • SE Thermo Fischer (Patheon)
  • Lakepharma, Inc.
  • Genscript
  • BioNova Scientific
  • BI BioXcellence
  • STC Biologics
図表

List of Tables

  • Table 1 Country share estimation
  • Table 2 List of Abbreviation
  • Table 3 List of secondary sources

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Biologics Contract Development market snapshot (2019)
  • Fig. 11 Biologics Contract Development market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Biologics Contract Development market product type outlook: Segment dashboard
  • Fig. 18 Biologics Contract Development market: product movement analysis
  • Fig. 19 Microbial market, 2016 - 2027 (USD Million)
  • Fig. 20 Mammalian market, 2016 - 2027 (USD Million)
  • Fig. 21 Others market, 2016 - 2027 (USD Million)
  • Fig. 22 Biologics Contract Development market product service outlook: Segment dashboard
  • Fig. 23 Biologics Contract Development market: product movement analysis
  • Fig. 24 Cell Line Development market, 2016 - 2027 (USD Million)
  • Fig. 25 Microbial Cell Line Development market, 2016 - 2027 (USD Million)
  • Fig. 26 Mammalian Cell Line Development market, 2016 - 2027 (USD Million)
  • Fig. 27 Others market, 2016 - 2027 (USD Million)
  • Fig. 28 Process development market, 2016 - 2027 (USD Million)
  • Fig. 29 Upstream Process Development market, 2016 - 2027 (USD Million)
  • Fig. 30 Microbial market, 2016 - 2027 (USD Million)
  • Fig. 31 Mammalian market, 2016 - 2027 (USD Million)
  • Fig. 32 Others market, 2016 - 2027 (USD Million)
  • Fig. 33 Downstream Process Development market, 2016 - 2027 (USD Million)
  • Fig. 34 Impurity, isolation, & identification market, 2016 - 2027 (USD Million)
  • Fig. 35 Physicochemical characterization market, 2016 - 2027 (USD Million)
  • Fig. 36 Pharmaceutical analysis market, 2016 - 2027 (USD Million)
  • Fig. 37 Others market, 2016 - 2027 (USD Million)
  • Fig. 38 MABS (Monoclonal Antibodies) market, 2016 - 2027 (USD Million)
  • Fig. 39 Recombinant proteins market, 2016 - 2027 (USD Million)
  • Fig. 40 Others market, 2016 - 2027 (USD Million)
  • Fig. 41 Others market, 2016 - 2027 (USD Million)
  • Fig. 42 Biologics Contract Development market product service outlook: Segment dashboard
  • Fig. 43 Biologics Contract Development market: product movement analysis
  • Fig. 44 Oncology market, 2016 - 2027 (USD Million)
  • Fig. 45 Immunological disorders market, 2016 - 2027 (USD Million)
  • Fig. 46 Cardiovascular disorders market, 2016 - 2027 (USD Million)
  • Fig. 47 Hematological disorders market, 2016 - 2027 (USD Million)
  • Fig. 48 Others market, 2016 - 2027 (USD Million)
  • Fig. 49 Regional market: Key takeaways
  • Fig. 50 Regional outlook, 2019 & 2027
  • Fig. 51 North America market, 2016 - 2027 (USD Million)
  • Fig. 52 The U.S. market, 2016 - 2027 (USD Million)
  • Fig. 53 Canada market, 2016 - 2027 (USD Million)
  • Fig. 54 Europe market, 2016 - 2027 (USD Million)
  • Fig. 55 The U.K. market, 2016 - 2027 (USD Million)
  • Fig. 56 Germany market, 2016 - 2027 (USD Million)
  • Fig. 57 France market, 2016 - 2027 (USD Million)
  • Fig. 58 Italy market, 2016 - 2027 (USD Million)
  • Fig. 59 Spain market, 2016 - 2027 (USD Million)
  • Fig. 60 Asia Pacific market, 2016 - 2027 (USD Million)
  • Fig. 61 China market, 2016 - 2027 (USD Million)
  • Fig. 62 India market, 2016 - 2027 (USD Million)
  • Fig. 63 Japan market, 2016 - 2027 (USD Million)
  • Fig. 64 Australia market, 2016 - 2027 (USD Million)
  • Fig. 65 South Korea market, 2016 - 2027 (USD Million)
  • Fig. 66 Latin America market, 2016 - 2027 (USD Million)
  • Fig. 67 Brazil market, 2016 - 2027 (USD Million)
  • Fig. 68 Mexico market, 2016 - 2027 (USD Million)
  • Fig. 69 Argentina market, 2016 - 2027 (USD Million)
  • Fig. 70 Colombia market, 2016 - 2027 (USD Million)
  • Fig. 71 MEA market, 2016 - 2027 (USD Million)
  • Fig. 72 South Africa market, 2016 - 2027 (USD Million)
  • Fig. 73 Saudi Arabia market, 2016 - 2027 (USD Million)
  • Fig. 74 UAE market, 2016 - 2027 (USD Million)
目次
Product Code: GVR-4-68038-983-8

Market Growth & Trends

The global biologics contract development market size is expected to reach USD 11.2 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.8% over the forecast period. The market comprises of organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications including drug screening, gene functional studies, and biologics production. The market is segmented on the basis of biological source, product service (Upstream and Downstream), and disease indication. Factors such as increasing adoption of advanced technologies for biologic development, favorable environment for clinical trials in developing countries, and an increase in outsourcing of R&D activities are paving way for the growth of the market.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and amalgamation of advanced and specialized technologies. For instance, in February 2020, LakePharma, Inc., and NJ Biopharmaceuticals LLC, a CRO, providing integrated chemistry and biology services, announced a strategic alliance to offer streamlined Antibody-Drug Conjugate (ADC) development solutions for biotechnology and pharmaceutical sectors. Many biopharma and pharma companies are increasingly looking for outsourcing their activities as it helps accelerate workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development and manufacturing organization market growth in the coming years.

Report Highlights:

  • Mammalian source emerged as the largest product segment in 2019, as the majority of research activities are being carried out using mammalian cell lines
  • The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs)
  • North America dominated the market in 2019. Increase in strategic acquisitions and partnerships and rise in demand for specialized testing services are likely to have a positive impact on the market
  • In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period.

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Source Type
    • 1.1.2. Product Service Type
    • 1.1.3. Disease Indication Type
    • 1.1.4. Regional Scope
    • 1.1.5. Estimates And Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. Gvr's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details Of Primary Research
  • 1.4. Information Or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
  • 1.6. Region Wise Market Calculation
    • 1.6.1. Region Wise Market: Base Estimates
    • 1.6.2. Global Market: Cagr Calculation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis (Model 1)
    • 1.7.2. Volume Price Analysis (Model 2)
      • 1.7.2.1. Service Segment Analysis
  • 1.8. List Of Primary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Secondary Sources
  • 1.11. Objectives
    • 1.11.1. Objective - 1:
    • 1.11.2. Objective - 2:
    • 1.11.3. Objective - 3:
    • 1.11.4. Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation and Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Increasing adoption of advanced technologies
    • 3.2.3 Increasing mergers and collaborations
    • 3.2.4 Favourable environment for clinical trials in developing countries
    • 3.2.5 Increasing outsourcing of R&D activities
    • 3.2.6 Market Restraint Analysis
    • 3.2.7 Intellectual property rights issues
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Biologics Contract Development: Market Analysis Tools
    • 3.4.1 Industry Analysis - Porter's
    • 3.4.2 PESTEL Analysis

Chapter 4 Biologics Contract Development Market: Source Type Segment Analysis

  • 4.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
    • 4.1.1 Microbial
      • 4.1.1.1 Microbial market, 2016 - 2027 (USD Million)
    • 4.1.2 Mammalian
      • 4.1.2.1 Mammalian market, 2016 - 2027 (USD Million)
    • 4.1.3 Others
      • 4.1.3.1 Others market, 2016 - 2027 (USD Million)

Chapter 5 Biologics Contract Development Market: Product Service Segment Analysis

  • 5.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
  • 5.2 Cell Line Development
    • 5.2.1 Cell Line Development Market, 2016 - 2027 (USD Million)
      • 5.2.1.1 Microbial Cell Line Development
      • 5.2.1.1.1 Microbial Cell Line Development Market, 2016 - 2027 (USD Million)
      • 5.2.1.2 Mammalian Cell Line Development
      • 5.2.1.2.1 Mammalian Cell Line Development Market, 2016 - 2027 (USD Million)
      • 5.2.1.3 Others
      • 5.2.1.3.1 Others Market, 2016 - 2027 (USD Million)
  • 5.3 Process Development
    • 5.3.1 Process Development Market, 2016 - 2027 (USD Million)
    • 5.3.2 Upstream Process Development
      • 5.3.2.1 Upstream Process Development Market, 2016 - 2027 (USD Million)
      • 5.3.2.1.1 Microbial
      • 5.3.2.1.2 Microbial Market, 2016 - 2027 (USD Million)
      • 5.3.2.1.3 Mammalian
      • 5.3.2.1.4 Mammalian Market, 2016 - 2027 (USD Million)
      • 5.3.2.1.5 Others
      • 5.3.2.1.6 Others Market, 2016 - 2027 (USD Million)
    • 5.3.3 Downstream Process Development
      • 5.3.3.1 Downstream Process Development, 2016 - 2027 (USD Million)
      • 5.3.3.1.1 Impurity, Isolation, & Identification
      • 5.3.3.1.3 Physicochemical Characterization
      • 5.3.3.1.4 Physicochemical Characterization Market, 2016 - 2027 (USD Million)
      • 5.3.3.1.5 Pharmaceutical Analysis
      • 5.3.3.1.6 Pharmaceutical Analysis Market, 2016 - 2027 (USD Million)
      • 5.3.3.1.7 Others
      • 5.3.3.1.8 Others Market, 2016 - 2027 (USD Million)
  • 5.4 Downstream Process, By Product
    • 5.4.1 Mabs (Monoclonal Antibodies)
      • 5.4.1.1 Mabs (Monoclonal Antibodies) Market, 2016 - 2027 (USD Million)
    • 5.4.2 Recombinant Proteins
      • 5.4.2.1 Recombinant Proteins Analysis Market, 2016 - 2027 (USD Million)
      • 5.4.2.1.1 Others
      • 5.4.2.1.2 Others Market, 2016 - 2027 (USD Million)
  • 5.5 Other Product Service (Quality And Regulatory Services, Etc)
    • 5.5.1 Others Market, 2016 - 2027 (USD Million)

Chapter 6 Biologics Contract Development Market: Disease Indication Segment Analysis

  • 6.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
  • 6.2 Oncology
    • 6.2.1 Oncology Market, 2016 - 2027 (USD Million)
  • 6.3 Immunological Disorders
    • 6.3.1 Immunological Disorders Market, 2016 - 2027 (USD Million)
  • 6.4 Cardiovascular Disorders
    • 6.4.1 Cardiovascular Disorders Market, 2016 - 2027 (USD Million)
  • 6.5 Haematological Disorders
    • 6.5.1 Haematological Disorders Market, 2016 - 2027 (USD Million)
    • 6.5.2 Others
      • 6.5.2.1 Others Market, 2016 - 2027 (USD Million)

Chapter 7 Biologics Contract Development Market: Regional Analysis

  • 7.1 Biologics Contract Development: Regional Market Share Analysis, 2019 & 2027
  • 7.2 North America
    • 7.2.1 North America Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.2.2 The U.S.
      • 7.2.2.1 The U.S. Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada Biologics Contract Development Market, 2016 - 2027 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.3.2 The U.K.
      • 7.3.2.1 The U.K. Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.3.3 Germany
      • 7.3.3.1 Germany Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.3.4 France
      • 7.3.4.1 France Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.3.5 Italy
      • 7.3.5.1 Italy Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.3.6 Spain
      • 7.3.6.1 Spain Biologics Contract Development Market, 2016 - 2027 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 China Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.4.3 India
      • 7.4.3.1 India Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.4.4 Japan
      • 7.4.4.1 Japan Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.4.5 Australia
      • 7.4.5.1 Australia Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.4.6 South Korea
      • 7.4.6.1 South Korea Biologics Contract Development Market, 2016 - 2027 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.5.5 Colombia
      • 7.5.5.1 Colombia Biologics Contract Development Market, 2016 - 2027 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Biologics Contract Development Market, 2016 - 2027 (USD Million)
    • 7.6.4 UAE
      • 7.6.4.1 UAE Biologics Contract Development Market, 2016 - 2027 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Company Profiles
  • 8.2 Company Profile
    • 8.2.1 Wuxi Biologics
      • 8.2.1.1 Company Overview
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Service Benchmarking
      • 8.2.1.4 Strategic Initiatives
    • 8.2.2 Abzena Ltd.
      • 8.2.2.1 Company Overview
      • 8.2.2.2 Service benchmarking
      • 8.2.2.3 Strategic Initiatives:
    • 8.2.3 FUJIFILM Diosynth Biotechnologies
      • 8.2.3.1 Company Overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Service benchmarking
      • 8.2.3.4 Strategic initiatives
    • 8.2.4 KBI Biopharma
      • 8.2.4.1 COMPANY overview
      • 8.2.4.2 Service Benchmarking
      • 8.2.4.3 Strategic Initiatives
    • 8.2.5 AGC Biologics
      • 8.2.5.1 Company Overview
      • 8.2.5.2 Financial performance
      • 8.2.5.3 Service Benchmarking
      • 8.2.5.4 Strategic Initiatives:
    • 8.2.6 SE Thermo Fischer (Patheon)
      • 8.2.6.1 Company Overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Service Benchmarking
      • 8.2.6.4 Strategic Initiatives:
    • 8.2.7 Lakepharma, Inc.
      • 8.2.7.1 Company overview
      • 8.2.7.2 Service Benchmarking
      • 8.2.7.3 Strategic Initiatives:
    • 8.2.8 Genscript
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial Performance
      • 8.2.8.3 Service Benchmarking
      • 8.2.8.4 Strategic Initiatives
    • 8.2.9 BioNova Scientific
      • 8.2.9.1 Company overview
      • 8.2.9.2 Service Benchmarking
    • 8.2.10 BI BioXcellence
      • 8.2.10.1 Company Overview
      • 8.2.10.2 Financial Performance
      • 8.2.10.3 SERVICE BENCHMARKING
      • 8.2.10.4 Strategic initiatives:
    • 8.2.11 STC Biologics
      • 8.2.11.1 Company Overview
      • 8.2.11.2 Service Benchmarking